Yoshikawa Tomohiro, Ide Tomohiro, Shimano Hitoshi, Yahagi Naoya, Amemiya-Kudo Michiyo, Matsuzaka Takashi, Yatoh Shigeru, Kitamine Tetsuya, Okazaki Hiroaki, Tamura Yoshiaki, Sekiya Motohiro, Takahashi Akimitsu, Hasty Alyssa H, Sato Ryuichiro, Sone Hirohito, Osuga Jun-Ichi, Ishibashi Shun, Yamada Nobuhiro
Department of Metabolic Diseases, Graduate School of Agricultural and Life Sciences, University of Tokyo, Bunkyo-ku, Japan.
Mol Endocrinol. 2003 Jul;17(7):1240-54. doi: 10.1210/me.2002-0190. Epub 2003 May 1.
Liver X receptors (LXRs) and peroxisome proliferator-activated receptors (PPARs) are members of nuclear receptors that form obligate heterodimers with retinoid X receptors (RXRs). These nuclear receptors play crucial roles in the regulation of fatty acid metabolism: LXRs activate expression of sterol regulatory element-binding protein 1c (SREBP-1c), a dominant lipogenic gene regulator, whereas PPARalpha promotes fatty acid beta-oxidation genes. In the current study, effects of PPARs on the LXR-SREBP-1c pathway were investigated. Luciferase assays in human embryonic kidney 293 cells showed that overexpression of PPARalpha and gamma dose-dependently inhibited SREBP-1c promoter activity induced by LXR. Deletion and mutation studies demonstrated that the two LXR response elements (LXREs) in the SREBP-1c promoter region are responsible for this inhibitory effect of PPARs. Gel shift assays indicated that PPARs reduce binding of LXR/RXR to LXRE. PPARalpha-selective agonist enhanced these inhibitory effects. Supplementation with RXR attenuated these inhibitions by PPARs in luciferase and gel shift assays, implicating receptor interaction among LXR, PPAR, and RXR as a plausible mechanism. Competition of PPARalpha ligand with LXR ligand was observed in LXR/RXR binding to LXRE in gel shift assay, in LXR/RXR formation in nuclear extracts by coimmunoprecipitation, and in gene expression of SREBP-1c by Northern blot analysis of rat primary hepatocytes and mouse liver RNA. These data suggest that PPARalpha activation can suppress LXR-SREBP-1c pathway through reduction of LXR/RXR formation, proposing a novel transcription factor cross-talk between LXR and PPARalpha in hepatic lipid homeostasis.
肝脏X受体(LXRs)和过氧化物酶体增殖物激活受体(PPARs)是核受体家族的成员,它们与视黄酸X受体(RXRs)形成 obligate 异二聚体。这些核受体在脂肪酸代谢调节中发挥关键作用:LXRs 激活固醇调节元件结合蛋白1c(SREBP-1c)的表达,SREBP-1c 是一种主要的脂肪生成基因调节因子,而 PPARα 促进脂肪酸β-氧化基因。在本研究中,研究了PPARs 对 LXR-SREBP-1c 途径的影响。在人胚肾293细胞中进行的荧光素酶测定表明,PPARα 和γ 的过表达剂量依赖性地抑制了由 LXR 诱导的 SREBP-1c 启动子活性。缺失和突变研究表明,SREBP-1c 启动子区域中的两个 LXR 反应元件(LXREs)负责 PPARs 的这种抑制作用。凝胶迁移试验表明,PPARs 减少了 LXR/RXR 与 LXRE 的结合。PPARα 选择性激动剂增强了这些抑制作用。在荧光素酶和凝胶迁移试验中,补充 RXR 减弱了 PPARs 的这些抑制作用,这暗示 LXR、PPAR 和 RXR 之间的受体相互作用是一种合理的机制。在凝胶迁移试验中 LXR/RXR 与 LXRE 的结合、通过免疫共沉淀在核提取物中 LXR/RXR 的形成以及通过对大鼠原代肝细胞和小鼠肝脏 RNA 的 Northern 印迹分析在 SREBP-1c 的基因表达中观察到了 PPARα 配体与 LXR 配体的竞争。这些数据表明,PPARα 的激活可以通过减少 LXR/RXR 的形成来抑制 LXR-SREBP-1c 途径,这提出了 LXR 和 PPARα 在肝脏脂质稳态中的一种新的转录因子相互作用。